FDA approved pemigatinib on 17 April 2020 as a second line for the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusions or rearrangements [76]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.